Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib Long-term Extension Study
2012-004225-24Phase 3Unknown
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ibrutinib in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), mantle cell lymphoma (MCL), follicular lymphoma (FL) and 1 more, sponsored by Janssen Pharmaceutical. Primary endpoint: Number of participants affected by an adverse event. Status: unknown.
02
Drugs
ibrutinib
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)mantle cell lymphoma (MCL)follicular lymphoma (FL)diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on 2012-004225-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-004225-24.